Characterizing the Use of Nabiximols (Δ9-Tetrahydrocannabinol-Cannabidiol) Buccal Spray in Pediatric Patients.

IF 0.6 Q4 PHARMACOLOGY & PHARMACY

CANADIAN JOURNAL OF HOSPITAL PHARMACY Pub Date : 2023-07-05 eCollection Date: 2023-01-01 DOI:10.4212/cjhp.3349

Lianne Hagg, Sarah Leung, Roxane Carr

{"title":"Characterizing the Use of Nabiximols (Δ9-Tetrahydrocannabinol-Cannabidiol) Buccal Spray in Pediatric Patients.","authors":"Lianne Hagg, Sarah Leung, Roxane Carr","doi":"10.4212/cjhp.3349","DOIUrl":null,"url":null,"abstract":"Background: Nabiximols is a commercially available cannabinoid buccal spray containing 2.7 mg Δ9-tetrahydrocannabinol (THC) and 2.5 mg cannabidiol (CBD) per spray. It is approved by Health Canada for adults with cancer pain or spasticity/neuropathic pain related to multiple sclerosis. Despite a lack of published studies regarding the use of nabiximols in children, it is being used in clinical practice for indications of pain, nausea/vomiting, and spasticity.Objective: To describe the use of nabiximols in children.Methods: This retrospective single-cohort study involved hospitalized pediatric patients who received at least 1 dose of nabiximols between January 2005 and August 2018. Descriptive statistical analyses were performed.Results: A total of 34 patients were included. The median age was 14 (range 0.6-18) years, and 11 patients (32%) were admitted under the oncology service. The median dose of nabiximols was 1.9 (range 0.3-10.8) sprays per day, and the median duration was 3.8 (range 1-213) days. Nabiximols was most commonly used to treat pain and nausea/vomiting and was most frequently prescribed by pain specialists. Perceived effectiveness was documented in 17 (50%) of the cases, with variable results being reported. The most commonly reported adverse effects were drowsiness and tachycardia (3/34, 9%, for each).Conclusion: In this study, nabiximols was prescribed for children in all age groups, for a variety of conditions, but most commonly for pain and nausea/vomiting. Further study, in the form of a large, prospective randomized controlled trial with clearly defined efficacy and safety end points for nausea/vomiting and/or pain, is needed to determine whether nabiximols is effective and safe in children.","PeriodicalId":51646,"journal":{"name":"CANADIAN JOURNAL OF HOSPITAL PHARMACY","volume":"76 3","pages":"216-220"},"PeriodicalIF":0.6000,"publicationDate":"2023-07-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10284286/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"CANADIAN JOURNAL OF HOSPITAL PHARMACY","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4212/cjhp.3349","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Nabiximols is a commercially available cannabinoid buccal spray containing 2.7 mg Δ9-tetrahydrocannabinol (THC) and 2.5 mg cannabidiol (CBD) per spray. It is approved by Health Canada for adults with cancer pain or spasticity/neuropathic pain related to multiple sclerosis. Despite a lack of published studies regarding the use of nabiximols in children, it is being used in clinical practice for indications of pain, nausea/vomiting, and spasticity.

Objective: To describe the use of nabiximols in children.

Methods: This retrospective single-cohort study involved hospitalized pediatric patients who received at least 1 dose of nabiximols between January 2005 and August 2018. Descriptive statistical analyses were performed.

Results: A total of 34 patients were included. The median age was 14 (range 0.6-18) years, and 11 patients (32%) were admitted under the oncology service. The median dose of nabiximols was 1.9 (range 0.3-10.8) sprays per day, and the median duration was 3.8 (range 1-213) days. Nabiximols was most commonly used to treat pain and nausea/vomiting and was most frequently prescribed by pain specialists. Perceived effectiveness was documented in 17 (50%) of the cases, with variable results being reported. The most commonly reported adverse effects were drowsiness and tachycardia (3/34, 9%, for each).

Conclusion: In this study, nabiximols was prescribed for children in all age groups, for a variety of conditions, but most commonly for pain and nausea/vomiting. Further study, in the form of a large, prospective randomized controlled trial with clearly defined efficacy and safety end points for nausea/vomiting and/or pain, is needed to determine whether nabiximols is effective and safe in children.

查看原文本刊更多论文

纳比西莫尔（Δ9-四氢大麻酚-卡那比二醇）口腔喷雾剂在儿科患者中的使用特点。

背景：Nabiximols 是一种市售大麻素口腔喷雾剂，每支喷雾剂含有 2.7 毫克 Δ9-四氢大麻酚（THC）和 2.5 毫克大麻二酚（CBD）。加拿大卫生部批准该药物用于治疗成人癌症疼痛或与多发性硬化症有关的痉挛/神经性疼痛。尽管缺乏有关纳比昔莫司在儿童中使用的公开研究，但它在临床实践中被用于疼痛、恶心/呕吐和痉挛等适应症：描述萘比西醇在儿童中的使用情况：这项回顾性单队列研究涉及 2005 年 1 月至 2018 年 8 月期间至少接受过一次纳比昔莫司治疗的住院儿科患者。结果：共纳入 34 名患者：共纳入 34 名患者。中位年龄为14岁（0.6-18岁），11名患者（32%）在肿瘤科住院。纳比西莫司的中位剂量为每天 1.9 次（0.3-10.8 次不等），中位持续时间为 3.8 天（1-213 天不等）。纳比西莫司最常用于治疗疼痛和恶心/呕吐，最常由疼痛专家开具处方。有 17 个病例（50%）记录了疗效，但报告的结果各不相同。最常报告的不良反应是嗜睡和心动过速（3/34，各占 9%）：在这项研究中，纳比昔莫司适用于所有年龄组的儿童，可用于治疗各种疾病，但最常见的是疼痛和恶心/呕吐。要确定纳比昔莫司对儿童是否有效和安全，还需要进行进一步的研究，研究的形式可以是大型前瞻性随机对照试验，明确规定恶心/呕吐和/或疼痛的疗效和安全性终点。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

CANADIAN JOURNAL OF HOSPITAL PHARMACY PHARMACOLOGY & PHARMACY-

CiteScore

1.10

自引率

0.00%

发文量

期刊介绍： The CJHP is an academic journal that focuses on how pharmacists in hospitals and other collaborative health care settings optimize safe and effective drug use for patients in Canada and throughout the world. The aim of the CJHP is to be a respected international publication serving as a major venue for dissemination of information related to patient-centred pharmacy practice in hospitals and other collaborative health care settings in Canada and throughout the world.